MDxHealth Updates on 2013 First-Half Results [Professional Services Close – Up]
| Proquest LLC |
Business Highlights
In a release on
Data supporting the ConfirmMDx test were published in peer- reviewed journals and presented at major scientific conferences. The data demonstrated that the biomarkers in the ConfirmMDx test outperform prostate specific antigen testing (PSA) and other traditional risk factors in prostate cancer detection, representing a powerful new tool for urologists assessing the need for a repeat prostate biopsy. Addtionally, investigators from the
On
Adoption of our ConfirmMDx for Prostate Cancer test in the U.S. continues to accelerate. Year to date we have tested more than 42,000 prostate biopsies from over 3,500 patients. This represents a sequential increase of 82 percent in volume in Q2 over Q1 2013," said Dr.
Commenting on the financial results, Dr. Groen continued: "We are pleased with the significant growth in commercial revenue thus far in 2013, derived from both diagnostic test and services sales. At this point more than 90 insurance companies have recognized the clinical utility and economic value and are reimbursing the ConfirmMDx for Prostate Cancer test. Our managed care efforts are focused on increasing coverage through contracts with third-party payors and networks. Reimbursement codes at these insurers and other third-party payors allow
Key limited audited financials, as of
Amounts as at and for the six months ended Euro thousands
Commercial revenue is defined as revenue without government grants and or subsidies, and includes
Revenues
Commercial revenue in H1 2013 amounted to
Test volumes for ConfirmMDx for Prostate Cancer continued to increase, with more than 4,500 tests sold to date since launch. A steady increase in reimbursement from private third-party payers was recorded during the period, with more than 90 insurers now paying for the test. This is expected to increase further through the agreements with
Operating Expenses
Operating expenses for 1H 2013 were
Non-operational and one-time restructuring costs, not expected to continue in future periods, amounted to
Results
As expected, 1H 2013 loss increased over the same period in 2012 due to costs associated with growing commercial infrastructure to support U.S. sales and marketing and new product R&D investment. The company's operating loss (EBIT) increased by 39.7 percent, and the net loss increased by 40.2 percent in H1 2013.
Cash Position
Outlook
Based on the growth in the first two quarters of 2013 we anticipate continued growth in test volumes, our customer base and payer reimbursement in coming quarters.
The central histopathology review of the company's second multicenter validation study for ConfirmMDx for Prostate Cancer has completed. The study involved five major cancer centers in the U.S. with Prof. Dr.
The reimbursement climate in the U.S. is still evolving. Along with our peers in the industry,
The Company's revenue recognition policy at this time is primarily based on cash collections. Because reported revenues generally exclude uncollected outstanding billable cases, the impact of current test sales on reported revenues may be delayed by one or more calendar quarters. However, as billing and reimbursement trends are established with each payer, the Company is transitioning to an accrual-based revenue recognition policy. Additionally,
Total operating costs in the second half are expected to increase in a carefully controlled manner in line with ramping up of the commercialization activities associated with the ConfirmMDx for Prostate Cancer test.
Post-closing events
In addition and as noted above, agreements were signed with
The
In the PharmacoMDx business area,
In early July,
Statutory Auditor's Limited Review Report
We have reviewed the accompanying interim consolidated statement of financial position of
We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the
((Comments on this story may be sent to newsdesk@closeupmedia.com))
| Copyright: | (c) 2013 ProQuest Information and Learning Company; All Rights Reserved. |
| Wordcount: | 1938 |


A.M. Best Affirms Ratings of Oman Insurance Company P.S.C. [Professional Services Close – Up]
Advisor News
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- New Va. subsidies help lure people back to health insurance
- 3 ways Crowley can make Healthcare more affordable in Wisconsin
3 ways to make healthcare more affordable in Wisconsin | Coleman Drake (Copy)
- Vermont public schools expect the lowest health insurance increase in years. For districts, it’s only a small relief.
- Vt. public schools expect the lowest health insurance increase in years
More Health/Employee Benefits NewsLife Insurance News
- Nebraska widow’s big win against life insurer in legal limbo
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
- NAIC task force to address LTC riders
More Life Insurance News